Saturday, May 18, 2013 Last update: 7:34 AM
Company Tech News as it Breaks
Trade Events
Exelixis, Inc.
News articles for Exelixis, Inc.:
Wednesday, May 15, 2013
- Reminder: Cabozantinib to be Featured in Nine Presentations at the 2013 ASCO Annual MeetingExelixis, Inc. (NASDAQ:EXEL) reiterated its slate of activities in conjunction with the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31-June 4, ... read more
Wednesday, May 8, 2013
- Exelixis Announces Webcasts of Upcoming Investor Conference PresentationsExelixis, Inc. (NASDAQ:EXEL) announced today that Michael M. Morrissey, Ph.D., the company’s president and chief executive officer, will present at two investor conferences this month. ... read more
Tuesday, May 7, 2013
- Exelixis Announces First Quarter 2013 Financial ResultsExelixis, Inc. (Nasdaq: EXEL) today reported financial results for the quarter ended March 31, 2013. Q1 2013 Highlights and Recent Events ... read moreCabozantinib to be Featured in Nine Presentations at the 2013 ASCO Annual MeetingExelixis, Inc. (NASDAQ:EXEL) announced today that cabozantinib will be the subject of nine separate data presentations at the upcoming 2013 Annual Meeting of the American Society of Clinical ... read more
Wednesday, April 17, 2013
- Exelixis Announces May 7th Webcast of First Quarter 2013 Financial Results Conference CallExelixis, Inc. (NASDAQ: EXEL) will release its first quarter 2013 financial results on Tuesday, May 7, 2013 after the markets close. The announcement will be followed by a ... read more
Tuesday, April 9, 2013
- Preclinical Data Presented at AACR Describe a Mechanism of Action of Cabozantinib in a Prostate Cancer Bone Metastasis ModelExelixis, Inc. (NASDAQ: EXEL) announced the presentation of preclinical data that provide insight into the mechanism of action of its lead compound, cabozantinib, with respect to its activity ... read more
Monday, February 25, 2013
- Exelixis Announces Webcast of March 4 Presentation at the 33rd Annual Cowen Health Care ConferenceExelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s president and chief executive officer, will present at the 33rd Annual Cowen Health Care Conference ... read more
Thursday, February 21, 2013
- Exelixis Selects Swedish Orphan Biovitrum AB as COMETRIQ™ European Distributor for Medullary Thyroid CancerExelixis, Inc. (NASDAQ:EXEL) and Swedish Orphan Biovitrum (Sobi) (STO: SOBI) today announced that they have entered into a three-year agreement to support the distribution and ... read moreExelixis Announces Fourth Quarter and Full Year 2012 Financial ResultsExelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and year ended December 31, 2012. Q4 2012 Highlights ... read more
Thursday, February 7, 2013
- Exelixis Announces February 21st Webcast of Fourth Quarter and Full Year 2012 Financial Results Conference CallExelixis, Inc. (NASDAQ: EXEL) will release its fourth quarter and full year 2012 financial results on Thursday, February 21, 2013 after the markets close. The announcement will be ... read more
Wednesday, February 6, 2013
- Exelixis Announces Webcast of February 12th Presentation at the 15th Annual BIO CEO & Investor ConferenceExelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s president and chief executive officer, will present at the 15th Annual BIO CEO & Investor ... read more
Thursday, December 13, 2012
- Exelixis Announces Webcast of January 9 Presentation at the J.P. Morgan 31st Annual Healthcare ConferenceExelixis, Inc. (NASDAQ: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s president and chief executive officer, will present at the J.P. Morgan 31st Annual Healthcare Conference ... read more
Thursday, November 29, 2012
- Exelixis Announces EMA Acceptance of Marketing Authorization Application For COMETRIQ™ (cabozantinib)Exelixis, Inc. (NASDAQ: EXEL) today announced the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for COMETRIQ™ (cabozantinib) for the proposed ... read moreFDA Approves COMETRIQ™ (Cabozantinib) for Treatment of Progressive, Metastatic Medullary Thyroid CancerExelixis, Inc. (NASDAQ: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved COMETRIQ™ (cabozantinib) for the treatment of progressive, metastatic medullary ... read more